The table below highlights the key differences between Semaglutide, Tirzepatide, and Retatrutide
A thorough medical assessment, including review of medical history and current medications, is essential before initiating treatment to ensure patient safety and optimise outcomes
Sara Siavoshi, DO, a triple-board-certified physician in neurology, headache medicine and obesity medicine, says these medications are approved for: Adults with obesity (meaning a BMI of 30 or higher) and adults who are overweight (a BMI of 27 or higher) and have a weight-related condition such as: Sleep apnea Type 2 diabetes Cardiovascular disease High blood pressure High cholesterol Dr
Obesity drugs alter eating behaviors More than half of participants said they had either a slight or large reduction in appetite with obesity therapy, including 54.4% of the Wegovy group, 62.1% of the Ozempic group and 56.5% of the Mounjaro group
Still, pharmaceutical companies are racing to investigate new, improved relatives of semaglutide